Results for tag: "Daclizumab"

Daclizumab is an immunosuppressive drug used to prevent organ rejection in patients who have undergone organ transplantation. It is a humanized monoclonal antibody that binds to the alpha subunit of the interleukin-2 receptor (IL-2Rα) on the surface of activated T cells. This binding prevents the T cells from responding to IL-2, which is necessary for their proliferation and survival. Daclizumab is typically used in combination with other immunosuppressive drugs, such as cyclosporine and corticosteroids. Daclizumab is approved for use in the United States, Europe, and other countries. It is marketed by Biogen under the brand name Zinbryta, and by AbbVie under the brand name Zenapax. Other companies involved in the daclizumab market include Merck, Novartis, and Roche. Show Less Read more